27
Jan

Lechleiter recently pointed to animal health as well as key therapeutic areas like neurosciences, diabetes and cancer, according to a report from Reuters.

…read more

Source: Lilly CEO Lechleiter joins the busy buyside in biotech

    

0 No comments